Acuitas: (noun) insight, perception, sharpness.

FEATURED

Acuitas Therapeutics Co-authors Study that Shows Promise for a Universal mRNA Flu Shot (Nov 2022)

Click to see a news release regarding a new study co-authored by scientists from the University of Pennsylvania and Acuitas Therapeutics that shows early promise for an mRNA vaccine targeting all known flu strains. More >

Acuitas Receives Life Sciences BC's Company of the Year Award (Sep 2022)

Click to see a news release on Acuitas Therapeutics being recognized as the 2022 Company of the Year by Life Sciences BC. More >

Acuitas President & CEO Named Pacific Winner in EY Entrepreneur of the Year Award Program (Jul 2022)

Click to see a news release regarding President & CEO, Dr. Thomas Madden, being named as one of seven Pacific winners in the EY Entrepreneur of the Year Award Program. More >

OTHER NEWS

Video Alert
News Alert
  • Nov. 30, 2022 – Click to see a news release regarding Acuitas Therapeutics co-authoring a study that shows early promise for an mRNA vaccine targeting all known flu strains. More >
  • Sep. 29, 2022 – Click to see a news release regarding President & CEO, Dr. Thomas Madden, receiving BIOTECanada’s 2022 Gold Leaf Award in the Game Changing Industry Leadership category. More >
  • Aug. 5, 2022 – Click to see a news release regarding Michael Artley joining Acuitas Therapeutics as Senior Director of Information Technology. More >
  • Jul. 13, 2022 – Click to see a news release regarding Acuitas Therapeutics’ President & CEO, Dr. Thomas Madden, being named a Pacific winner in the EY Entrepreneur of the Year Award Program. More >
  • Jul. 8, 2022 – Click to see a news release regarding Acuitas Therapeutics being named this year’s recipient of Life Sciences BC’s Company of the Year award. More >
  • Apr. 27, 2022 – Click to see a news release regarding the founders of Acuitas Therapeutics, Drs. Pieter Cullis, Michael Hope and Thomas Madden, being named as Governor General’s Innovation Award recipients. More >
  • Apr. 4, 2022 – Click to see a news release regarding Abi Coman-Walker’s promotion to Chief Operating Officer. More >
  • Mar. 7, 2022 – Click to see a news release regarding an Acuitas Therapeutics donation to the Canadian Red Cross to support humanitarian efforts in Ukraine. More >
  • Jan. 31, 2022 – Click to see a news release regarding an Acuitas Therapeutics sponsorship agreement with the Greater Vancouver Regional Science Fair. More >
  • Jan. 24, 2022 – Click to see a news release regarding an Acuitas Therapeutics partnership agreement with Science World, Vancouver. More >
  • Jan. 17, 2022 – Click to see a news release regarding an Acuitas Therapeutics sponsorship agreement with the Vancouver Athletic Football Club. More >
  • Jan. 12, 2022 – Click to see a news release regarding Miranda Lam joining Acuitas Therapeutics as Chief Legal Officer & Sr. Director, Business Development. More >
  • Jan. 10, 2022 – Click to see a news release regarding Pfizer entering into an agreement with Acuitas for use of our lipid nanoparticle delivery system for mRNA vaccines and therapeutics. More >
  • Jan. 4, 2022 – Click to see a news release regarding Acuitas co-founder Dr. Pieter Cullis named an Officer of the Order of Canada. More >
  • Nov. 25, 2021 – Click to see a news release regarding Acuitas co-founder Dr. Pieter Cullis named a co-winner of the 2021 Prince Mahidol Award for medicine. More >
  • Sep. 23, 2021 – Click to see a news release regarding Acuitas Therapeutics receiving the Global Impact Award from Life Sciences BC. More >
  • Jul. 27, 2021 – Click to see a news release regarding Steve Arns joining Acuitas Therapeutics as the Director of Chemistry. More >
  • May 19, 2021 – Click to see a news release regarding publication of Acuitas research results in the prestigious journal Nature Biotechnology, from the company’s work as part of a collaboration with Dr. Schwank. More >
  • May 19, 2021 – Click to see a news release regarding publication of Acuitas research results in the prestigious journal Nature, from the company’s work as part of a collaboration with Verve Therapeutics, Inc. More >
  • Apr. 5, 2021 – Click to see a news release regarding Abi Coman-Walker joining Acuitas Therapeutics as the Finance & Operations Senior Director. More >
  • Feb. 5, 2021 – Click to see a news release regarding Dr. Madden’s participation in a panel led by the prestigious Gairdner Foundation. More >
  • Dec. 9, 2020 – Click to see a news release regarding our partner, BioNTech (with Pfizer), on the Health Canada emergency use authorization of their COVID-19 vaccine. Our proprietary lipid nanoparticles are an important aspect of BioNTech’s mRNA vaccine. More >
  • Nov. 9, 2020 – Click to see a news release regarding our partner, BioNTech, and their Phase 3 data for a COVID-19 vaccine. Our proprietary lipid nanoparticles are an important aspect of BioNTech’s mRNA vaccine. More >
  • Nov. 3, 2020 – Click to see a news release regarding our partner, CureVac, and their clinical trial data for a COVID-19 vaccine. Our proprietary lipid nanoparticles are an important aspect of CureVac’s mRNA vaccine. More >
  • Jul. 1, 2020 – Click to see a news release regarding our partner, BioNTech, and their clinical trial data for a COVID-19 vaccine. Our proprietary lipid nanoparticles are an important aspect of BioNTech’s mRNA vaccine. More >
  • Mar. 30, 2020 – Our President and CEO, Dr. Thomas Madden, has been inducted into the very prestigious American Institute for Medical and Biological Engineering (AIMBE) College of Fellows. More >
Publication Alert
  • Nov. 24, 2022 – Collaboration with Scott Hensley’s group at UPenn on the development of a multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes (Science 2022). More >
  • Aug. 9, 2022 – Collaboration with Dr. Pardi on the development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses (Nature Communications 2022). More >
  • May 16, 2022 – Collaboration with Precision BioSciences on a study targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo (Molecular Therapy 2022). More >
  • Mar. 15, 2022 – Collaboration with Zekun Mu and Dr. Barton Haynes of Duke Human Vaccine Institute on a study that shows mRNA vaccine technology can be used for HIV vaccines (Cell Reports 2022). More >
  • Jan. 6, 2022 – Collaboration with University of Pennsylvania investigators Jonathan Epstein and Drew Weissman in designing an immunotherapy strategy to generate transient chimeric antigen receptor (CAR) T cells that can recognize the fibrotic cells in the heart (Science 2022). More >
  • Jun. 21, 2021 – Collaboration with Dr. Angov in the development of messenger RNA expressing PfCSP that induces functional, protective immune responses against malaria in mice (Walter Reed Army Institute of Research 2021). More >
  • May 19, 2021 – Collaboration with Dr. Schwank in the development of in vivo adenine base editing of PCSK9 in macaques that reduce LDL cholesterol levels (Nat Biotech 2021). More >
  • May 19, 2021 – Collaboration with Verve Therapeutics, Inc. in the development of non-viral lipid nanoparticle (LNP) delivery technologies for single-course in vivo, liver-targeted gene editing treatments for cardiovascular disease, the leading cause of death worldwide (Nature 2021). More >
  • Jan. 27, 2021 – Collaboration with Dr. Weissman in the development of murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA (Nature Communications 2021). More >
  • Jan. 26, 2021 – Collaboration with Dr. Schwank in the development of in vivo cytidine base editing of hepatocytes without detectable off-target mutations in RNA and DNA (Nature Biomedical Engineering 2021). More >
  • Dec. 24, 2020 – Collaboration with Dr. Weissman in the development of D614G spike mutation that increases SARS CoV-2 susceptibility to neutralization (Cell Host Microbe 2020). More >
  • Dec. 1, 2020 – Collaboration with Dr. Locci in the development of potent antigen-specific germinal center responses associated with neutralizing antibody generation in SARS-CoV-2 mRNA vaccines (Immunity 2020). More >
  • Aug. 25, 2020 – Collaboration with Dr. Pardi in the development of nucleoside-modified mRNA vaccines against SARS-CoV-2 (Immunity 2020). More >
  • Jul. 9, 2020 – Collaboration with Dr. Shattock in the development of a SARS-CoV2 vaccine using self-amplifying RNA encapsulated in LNP (Nat Commun 2020). More >
  • Jun. 30, 2020 – Collaboration with Dr. Nachbagauer in the development of a universal influenza virus vaccine (Mol Ther 2020). More >
  • Jun. 30, 2020 – Collaboration with Dr. Kurtis in the development of a vaccine based on PfGARP that partially protects subjects against malaria challenge (Nature 2020). More >
  • Jan. 30, 2020 – Collaboration with Dr. Muzykantov in the development of mRNA-LNP targeting cerebral Vasculature (Proc Natl Acad Sci U S A. 2020). More >
  • Jan. 30, 2020 – Collaboration with Dr. Hensley in the development of mRNA-LNP vaccine for infants (Sci Transl Med. 2020). More >
  • Sep. 20, 2019 – Collaboration with Dr. Sanders in the delivery of self-amplifying mRNA with LNPs (Mol Ther Nucleic Acids 2019). More >
  • Apr. 12, 2019 – Collaboration with Dr. Weissman in the development of mRNA-LNP for HIV vaccine (Mol Ther Nucleic Acids 2019). More >
  • Apr. 12, 2019 – Collaboration with Dr. Lee and colleagues in the development of ZFN mRNA-LNP for in vivo genome editing (Mol Ther 2019). More >
  • Nov. 22, 2018 – Collaboration with Dr. Muzykantov in the development of targeting mRNA-LNP (J Control Release 2018 Dec 10;291:106-115). More >
  • Aug. 22, 2018 – Collaboration with Dr. Weissman in the development of broadly protective/universal influenza virus vaccine using mRNA-LNP (Nat Commun. 2018 Aug. 22; 9(1): 3361). More >